Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer

[1]  David R. Piper,et al.  SYNGAP1 Controls the Maturation of Dendrites, Synaptic Function, and Network Activity in Developing Human Neurons , 2020, The Journal of Neuroscience.

[2]  Gary D Bader,et al.  Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. , 2020, Epigenomics.

[3]  Luke A. Gilbert,et al.  DNA methylation landscapes in advanced prostate cancer , 2020, Nature Genetics.

[4]  Gary D Bader,et al.  Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment , 2020, bioRxiv.

[5]  O. Elemento,et al.  Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. , 2020, The Journal of clinical investigation.

[6]  F. Saad,et al.  Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. , 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[7]  R. Huang,et al.  RNA-binding protein ZFP36L1 suppresses hypoxia and cell cycle signaling. , 2020, Cancer research.

[8]  A. Zoubeidi,et al.  The epigenetic and transcriptional landscape of neuroendocrine prostate cancer. , 2019, Endocrine-related cancer.

[9]  Henry W. Long,et al.  CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer , 2019, Cell reports.

[10]  Joshua A. Riback,et al.  Structural basis for adhesion G protein-coupled receptor Gpr126 function , 2019, Nature Communications.

[11]  Christopher J. Nelson,et al.  Histone Chaperone Paralogs Have Redundant, Cooperative, and Divergent Functions in Yeast , 2019, Genetics.

[12]  P. Nelson,et al.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. , 2019, The Journal of clinical investigation.

[13]  N. Kaakoush,et al.  OPCML: A Promising Biomarker and Therapeutic Avenue. , 2019, Trends in cancer.

[14]  A. Zoubeidi,et al.  PEG10 is associated with treatment-induced neuroendocrine prostate cancer. , 2019, Journal of molecular endocrinology.

[15]  Haiyang Xie,et al.  COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer , 2019, International journal of oncology.

[16]  Wenyan Wang,et al.  Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway , 2019, Cancer Cell International.

[17]  H. Beltran,et al.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies. , 2018, Cold Spring Harbor perspectives in medicine.

[18]  M. Gleave,et al.  2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). , 2019, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[19]  V. Conteduca,et al.  Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test , 2018, Prostate Cancer and Prostatic Diseases.

[20]  Joshua M. Stuart,et al.  Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Hostetter,et al.  Notch3 Promotes Prostate Cancer-Induced Bone Lesion Development via MMP-3 , 2018, bioRxiv.

[22]  I. V. Kovtun,et al.  Frequently rearranged and overexpressed δ-catenin is responsible for low sensitivity of prostate cancer cells to androgen receptor and β-catenin antagonists , 2018, Oncotarget.

[23]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[24]  Wun-Jae Kim,et al.  WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages , 2018, British Journal of Cancer.

[25]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[26]  Jan-Gowth Chang,et al.  Upregulated SLC22A3 has a potential for improving survival of patients with head and neck squamous cell carcinoma receiving cisplatin treatment , 2017, Oncotarget.

[27]  N. Sharifi,et al.  Androgen Signaling in Prostate Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[28]  Yuan Tian,et al.  ChAMP: updated methylation analysis pipeline for Illumina BeadChips , 2017, Bioinform..

[29]  H. Van Vlierberghe,et al.  The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma , 2017, Oncogene.

[30]  D. Herr,et al.  G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. , 2017, Biochimica et biophysica acta. Molecular cell research.

[31]  Haojie Huang,et al.  CXCL13 is androgen-responsive and involved in androgen induced prostate cancer cell migration and invasion. , 2017, Oncotarget.

[32]  James E. Verdone,et al.  The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion , 2017, Molecular oncology.

[33]  E. Crawford,et al.  Navigating the evolving therapeutic landscape in advanced prostate cancer. , 2017, Urologic oncology.

[34]  Zhao-You Tang,et al.  Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma. , 2017, American journal of cancer research.

[35]  I. Mills,et al.  The importance of DNA methylation in prostate cancer development , 2017, The Journal of Steroid Biochemistry and Molecular Biology.

[36]  M. Rubin,et al.  The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. , 2017, Cancer discovery.

[37]  Kaitlyn M. Gayvert,et al.  N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. , 2016, Cancer cell.

[38]  Peter A. Jones,et al.  Epigenetic Determinants of Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[39]  Q. Tao,et al.  Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer , 2016, Oncotarget.

[40]  S. Yegnasubramanian.  Prostate cancer epigenetics and its clinical implications , 2016, Asian journal of andrology.

[41]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[42]  Jovana Maksimovic,et al.  missMethyl: an R package for analyzing data from Illumina's HumanMethylation450 platform , 2016, Bioinform..

[43]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[44]  Robert H. Bell,et al.  The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. , 2015, Cell reports.

[45]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[46]  K. Miller,et al.  Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[47]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[48]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[49]  M. Jaggi,et al.  Slit/Robo pathway: a promising therapeutic target for cancer. , 2015, Drug discovery today.

[50]  V. Fiano,et al.  Global DNA hypomethylation in prostate cancer development and progression: a systematic review , 2014, Prostate Cancer and Prostatic Disease.

[51]  Amos Tanay,et al.  Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer. , 2014, Cell reports.

[52]  R. Ferraldeschi,et al.  Evolution of androgen receptor targeted therapy for advanced prostate cancer , 2014, Nature Reviews Clinical Oncology.

[53]  M. Gleave,et al.  Castration-resistant prostate cancer: from new pathophysiology to new treatment. , 2014, European urology.

[54]  F. Saad,et al.  Management of Castration Resistant Prostate Cancer , 2014 .

[55]  Víctor Quesada,et al.  Cell–cell adhesion genes CTNNA2 and CTNNA3 are tumour suppressors frequently mutated in laryngeal carcinomas , 2013, Nature Communications.

[56]  N. Ahituv,et al.  The role of AUTS2 in neurodevelopment and human evolution. , 2013, Trends in genetics : TIG.

[57]  S. Badve,et al.  ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. , 2013, Cancer research.

[58]  M. Gleave,et al.  Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. , 2013, Cancer research.

[59]  M. Gleave,et al.  A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[60]  Martin J. Aryee,et al.  DNA Methylation Alterations Exhibit Intraindividual Stability and Interindividual Heterogeneity in Prostate Cancer Metastases , 2013, Science Translational Medicine.

[61]  I. Mills,et al.  The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. , 2013, Cancer cell.

[62]  Francesco Marabita,et al.  A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data , 2012, Bioinform..

[63]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[64]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[65]  Zelmina Lubovac,et al.  The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors , 2012, BMC Cancer.

[66]  H. Schayek,et al.  Global Methylation Analysis Identifies PITX2 as an Upstream Regulator of the Androgen Receptor and IGF-I Receptor Genes in Prostate Cancer , 2012, Hormone and Metabolic Research.

[67]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[68]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[69]  G. Djordjević,et al.  Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study. , 2010, Collegium antropologicum.

[70]  N. Oue,et al.  Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase , 2010, Oncogene.

[71]  N. Tallada,et al.  An Immunohistochemical Study , 1992 .